TenNor of Suzhou Raises $25 Million for Dual-Action Antibiotics
September 19, 2016 at 09:03 AM EDT
TenNor Therapeutics of Suzhou announced a $25 million Series B financing led by Northern Light Venture Capital. TenNor is developing novel dual-acting antibiotics for unmet needs.The company's lead product, TNP-2092, is an oral capsule that treats gastrointestinal tract bacterial infections, especially digestive diseases associated with Helicobacter pylori. The funding will be used to support a China Phase III trial of TNP-2092. More details.... Share this with colleagues: // //